PAVmed, Inc. (PAVM)

NASDAQ:
PAVM
| Latest update: Apr 15, 2026, 6:28 PM

Stock events for PAVmed, Inc. (PAVM)

PAVmed's stock price has been influenced by a reverse stock split, business and financial updates, a leadership appointment, conference participation, ownership filings, and stock performance. The company announced a reverse stock split to address Nasdaq's minimum bid price requirement. PAVmed provided a business update and reported its fourth quarter and full-year 2025 financial results. Joseph Virgilio was appointed to lead its relaunched medical device portfolio. Lucid Diagnostics participated in the 25th Annual Needham Virtual Healthcare Conference. Recent SEC filings disclosed significant ownership stakes by individuals. While the stock experienced a decline over the past year, it showed an increase over the past six months.

Demand Seasonality affecting PAVmed, Inc.’s stock price

Information regarding the specific demand seasonality for PAVmed Inc.'s products and services is not publicly available in the provided search results.

Overview of PAVmed, Inc.’s business

PAVmed Inc. is a commercial-stage medical technology company focused on acquiring, developing, and commercializing novel products that address unmet medical needs in the United States. Its major products and pipeline include CarpX, EsoCheck Esophageal Cell Collection Device, EsoGuard Esophageal DNA Test, EsoCure Esophageal Ablation Device, PortIO, Veris Cancer Care Platform, Lucid Diagnostics Inc. (subsidiary), and Veris Health Inc. (subsidiary).

PAVM’s Geographic footprint

PAVmed Inc. is headquartered in New York, New York, United States, with a focus on targeting unmet medical needs in the United States.

PAVM Corporate Image Assessment

PAVmed's brand reputation has been influenced by its efforts to strengthen its financial position and advance its product pipeline. Positive events include Lucid Diagnostics processing a record volume of EsoGuard tests, securing initial concierge medicine contracts, and obtaining its first commercial insurance coverage policies. PAVmed also strengthened its capital structure and relaunched its medical device portfolio under new leadership. The company's focus on innovation in medical devices, diagnostics, and digital health contributes to its reputation.

Ownership

PAVmed Inc. has a mix of institutional and individual owners. Major institutional shareholders include Captrust Financial Advisors, SBI Securities Co., Ltd., and AdvisorNet Financial, Inc. Ira Scott Greenspan is noted as the largest individual shareholder. Other significant individual insiders include Matthew Sirovich, Tasso Partners LLC, Lishan Aklog, Dennis M. McGrath, and Joshua R. Lamstein.

Expert AI

Show me the sentiment for PAVmed, Inc.
What's the latest sentiment for PAVmed, Inc.?

Price Chart

$9.36

2.13%
(1 month)

Top Shareholders

FMC Group Holdings LP
2.41%
The Vanguard Group, Inc.
1.15%
UBS Group AG
0.74%
Jane Street Group LLC
0.68%
Geode Holdings Trust
0.57%
Northern Trust Corp.
0.36%
BlackRock, Inc.
0.24%
Philadelphia Trading, Inc.
0.23%

Trade Ideas for PAVM

Today

Sentiment for PAVM

News
Social

Buzz Talk for PAVM

Today

Social Media

FAQ

What is the current stock price of PAVmed, Inc.?

As of the latest update, PAVmed, Inc.'s stock is trading at $9.36 per share.

What’s happening with PAVmed, Inc. stock today?

Today, PAVmed, Inc. stock is up by 2.13%, possibly due to news.

What is the market sentiment around PAVmed, Inc. stock?

Current sentiment around PAVmed, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is PAVmed, Inc.'s stock price growing?

Over the past month, PAVmed, Inc.'s stock price has increased by 2.13%.

How can I buy PAVmed, Inc. stock?

You can buy PAVmed, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol PAVM

Who are the major shareholders of PAVmed, Inc. stock?

Major shareholders of PAVmed, Inc. include institutions such as FMC Group Holdings LP (2.41%), The Vanguard Group, Inc. (1.15%), UBS Group AG (0.74%) ... , according to the latest filings.